In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach

BACKGROUND: Doxorubicin (DOX) and its pegylated liposomal formulation (L_DOX) are the standard of care for triple-negative breast cancer (TNBC). However, resistance to DOX often occurs, motivating the search for alternative treatment approaches. The retinoblastoma protein (Rb) is a potential pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleisher, Brett, Lezeau, Jovin, Werkman, Carolin, Jacobs, Brehanna, Ait-Oudhia, Sihem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899308/
https://www.ncbi.nlm.nih.gov/pubmed/33628047
http://dx.doi.org/10.2147/BCTT.S292161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899308/
https://www.ncbi.nlm.nih.gov/pubmed/33628047
http://dx.doi.org/10.2147/BCTT.S292161

Ejemplares similares